Patents by Inventor Douglas F. Nixon

Douglas F. Nixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors
    Patent number: 11261231
    Abstract: The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: March 1, 2022
    Assignees: Altor BioScience, LLC., The Regents of the University of Califoria
    Inventors: Richard B. Jones, Mario Ostrowski, Douglas F. Nixon, Lishomwa C. Ndhlovu, James Rini
  • Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
    Patent number: 10981976
    Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 20, 2021
    Assignees: University of Rochester, Oregon Health & Science University, George Washington University
    Inventors: James J. Kobie, Jonah B. Sacha, Douglas F. Nixon
  • Human Monoclonal Antibodies to Human Endogenous Retrovirus K Envelope (HERV-K) and Use Thereof
    Publication number: 20200140527
    Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.
    Type: Application
    Filed: August 30, 2017
    Publication date: May 7, 2020
    Applicant: University of Rochester
    Inventors: James J. Kobie, Jonas B. Sacha, Douglas F. Nixon
  • Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
    Patent number: 9572873
    Abstract: Isolated polypeptides related to endogenous anti-viral polypeptides; and compositions, including immunogenic compositions, comprising a subject isolated polypeptide are disclosed herein. A subject isolated polypeptide comprises an amino acid sequence having substantial amino acid sequence identity to a contiguous stretch of amino acids of one or more endogenous anti-viral polypeptides, wherein the endogenous anti-viral polypeptides are polypeptides subject to proteolytic degradation as a result of the activity of one or more viral proteins. Also provided are diagnostic and treatment methods using the subject isolated polypeptides and compositions.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: February 21, 2017
    Assignee: The Regents of the University of California
    Inventors: Douglas F. Nixon, Stephane Champiat, Keith Garrison
  • Therapeutic and Diagnostic Methods Using TIM-3
    Publication number: 20160311890
    Abstract: The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.
    Type: Application
    Filed: July 13, 2016
    Publication date: October 27, 2016
    Inventors: Richard B. Jones, Mario Ostrowski, Douglas F. Nixon, Lishomwa C. Ndhlovu, James Rini
  • Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
    Patent number: 9416165
    Abstract: The application relates to methods of treating a chronic viral infection, such as HIV (Human Immunodeficiency Virus), by modulating Tim-3 activity, whereby blocking the action of Tim-3 on a T cell enhances the immunity to the virus.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: August 16, 2016
    Assignees: The Regents of the University of California
    Inventors: Richard B. Jones, Mario Ostrowski, Douglas F. Nixon, Lishomwa C. Ndhlovu, James Rini
  • T-CELL IMMUNOGENS DERIVED FROM ANTI-VIRAL PROTEINS AND METHODS OF USING SAME
    Publication number: 20160151470
    Abstract: Isolated polypeptides related to endogenous anti-viral polypeptides; and compositions, including immunogenic compositions, comprising a subject isolated polypeptide are disclosed herein. A subject isolated polypeptide comprises an amino acid sequence having substantial amino acid sequence identity to a contiguous stretch of amino acids of one or more endogenous anti-viral polypeptides, wherein the endogenous anti-viral polypeptides are polypeptides subject to proteolytic degradation as a result of the activity of one or more viral proteins. Also provided are diagnostic and treatment methods using the subject isolated polypeptides and compositions.
    Type: Application
    Filed: July 7, 2015
    Publication date: June 2, 2016
    Inventors: Douglas F. Nixon, Stephane Champiat, Keith Garrison
  • T-cell immunogens derived from anti-viral proteins and methods of using same
    Patent number: 9084762
    Abstract: Isolated polypeptides related to endogenous anti-viral polypeptides; and compositions, including immunogenic compositions, comprising a subject isolated polypeptide are disclosed herein. A subject isolated polypeptide comprises an amino acid sequence having substantial amino acid sequence identity to a contiguous stretch of amino acids of one or more endogenous anti-viral polypeptides, wherein the endogenous anti-viral polypeptides are polypeptides subject to proteolytic degradation as a result of the activity of one or more viral proteins. Also provided are diagnostic and treatment methods using the subject isolated polypeptides and compositions.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: July 21, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Douglas F. Nixon, Stephane Champiat, Keith Garrison
  • Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof
    Publication number: 20130323279
    Abstract: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 5, 2013
    Applicants: The J. David Gladstone Institutes, Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of California, The Governing Counicl of University of Toronto
    Inventors: Douglas F. Nixon, Keith E. Garrison, Duncan A. Meiklejohn, Mario A. Ostrowski, R. Bradley Jones, Ashish Agrawal, Jack Lenz, Seth Rakoff-Nahoum, Frederick M. Hecht
  • T-Cell Immunogens Derived from Anti-Viral Proteins and Methods of Using Same
    Publication number: 20110274709
    Abstract: Isolated polypeptides related to endogenous anti-viral polypeptides; and compositions, including immunogenic compositions, comprising a subject isolated polypeptide are disclosed herein. A subject isolated polypeptide comprises an amino acid sequence having substantial amino acid sequence identity to a contiguous stretch of amino acids of one or more endogenous anti-viral polypeptides, wherein the endogenous anti-viral polypeptides are polypeptides subject to proteolytic degradation as a result of the activity of one or more viral proteins. Also provided are diagnostic and treatment methods using the subject isolated polypeptides and compositions.
    Type: Application
    Filed: September 28, 2009
    Publication date: November 10, 2011
    Inventors: Douglas F. Nixon, Stephane Champiat, Keith Garrison
  • Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof
    Publication number: 20110046042
    Abstract: The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers that are associated with tissues in which LINE polypeptides are aberrantly expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a LINE polypeptide.
    Type: Application
    Filed: September 19, 2008
    Publication date: February 24, 2011
    Applicants: THE J. DAVID GLADSTONE INSTITUTES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Douglas F. Nixon, Keith Garrison, Duncan Meiklejohn, Mario Ostrowski, R. Bradley Jones, Ashish Agrawal, Frederick M. Hecht
  • Therapeutic and Diagnostic Methods Using TIM-3
    Publication number: 20100247521
    Abstract: The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.
    Type: Application
    Filed: October 27, 2008
    Publication date: September 30, 2010
    Inventors: Richard B. Jones, Mario Ostrowski, Douglas F. Nixon, Lishomwa C. Ndhlovu, James Rini
  • HIV-1 core protein fragments
    Patent number: 5480967
    Abstract: The present invention provides peptidal fragments of human immunodeficiency virus (HIV) which interact specifically with a particular human leucocyte antigen (HLA) class I molecule to stimulate cytotoxic T lymphocyte immunity.
    Type: Grant
    Filed: July 6, 1992
    Date of Patent: January 2, 1996
    Assignee: United Biomedical, Inc.
    Inventors: Andre J. McMichael, Douglas F. Nixon, Alain R. M. Townsend, Frances M. Gotch
  • Peptide fragments of HIV
    Patent number: 5459238
    Abstract: Peptides are described which have the amino acid sequence of a fragment of HIV (human immunodeficiency virus) which interacts specifically with a particular human leucocyte antigen (HLA) class I molecule, to stimulate cytotoxic T lymphocyte immunity. Such fragments can be used in a potential vaccine against AIDS (acquired immune deficiency syndrome), and for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 31, 1992
    Date of Patent: October 17, 1995
    Assignee: United Biomedical, Inc.
    Inventors: Andrew J. McMichael, Douglas F. Nixon, Alain R. M. Townsend
  • Assay for cytotoxic T cells
    Patent number: 5395751
    Abstract: A method of detecting in a sample CTL specific for a particular virus, e.g. HIV, comprises contacting the sample with a support carrying immobilized antibodies to a surface antigen on T cells; separating the support and attached materials; contacting the separated support with target cells matched to the HLA type of the source of the sample and with HLA matched peptide epitope of the virus that interacts with the CTL of interest; and monitoring lysis of the target cells.
    Type: Grant
    Filed: February 26, 1993
    Date of Patent: March 7, 1995
    Assignee: United Biomedical, Inc.
    Inventors: Andrew J. McMichael, Douglas F. Nixon, Frances M. Gotch